evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract,articles/11/pmid,articles/11/title,articles/11/journal,articles/11/pubDate,articles/11/volume,articles/11/issue,articles/11/pages,articles/11/authors,articles/11/elocationId,articles/11/link,articles/11/reference,articles/11/abstract,articles/12/pmid,articles/12/title,articles/12/journal,articles/12/pubDate,articles/12/volume,articles/12/issue,articles/12/pages,articles/12/authors,articles/12/elocationId,articles/12/link,articles/12/reference,articles/12/abstract
17680,GENE_BACKGROUND,,"The DIS3 gene encodes the catalytic subunit of the RNA exosome complex, prominently participating in RNA processing and quality control pathways. DIS3 catalytic activity is governed by the endoribonucleolytic (PIN) and the 3’–5’ exoribonucleolyitic (RNB) domains (PMID: 21289487). DIS3 affects the RNA-processing machinery and genetic alterations of DIS3, such as copy number gains and increased mRNA expression, were recently described in colorectal cancer (PMID: 23319804, 24478024). Additionally, a recent study in melanoma cell lines showed that overexpression and increased DNA copy number in the region of DIS3 may play a role in the aggressive phenotype of nodular melanoma cells (PMID: 21343389). In contrast, loss-off-function mutations in the DIS3 gene have been described in multiple myeloma (MM), suggesting a possible mechanism to disrupt protein translation (PMID: 21430775). Recently, the DIS3 gene has emerged as recurrently mutated in patients with MM from initial whole-genome (WGS) and exome (WES) sequencing studies (PMID: 21430775, 24434212, 22573403, 25521164, 23396385, 22237025). Some DIS3 mutations identified in MM were shown to interfere with its exonucleolytic activity, causing aberrant RNA metabolism and slower proliferation rates in cell lines (PMID: 24150935). Furthermore, DIS3 facilitates the maturation of the tumor suppressor let-7 miRNAs by reducing the stability of LIN28B, an inhibitor of let-7 processing. Through the reduction of mature let-7, DIS3 enhances the translation of let-7 targets such as MYC and RAS, leading to enhanced tumorigenesis (PMID: 25925570). Next-generation sequencing analysis of the DIS3 PIN and RNB domains in purified bone marrow plasma cell (PC) dyscrasia from 164 representative patients, including 130 cases with MM, 24 with primary PC leukemia and 10 with secondary PC leukemia) found DIS3 mutations respectively in 18.5%, 25% and 30% of cases (PMID: 26305418). Gene expression profiling analysis in DIS3-mutated patients identified a transcriptional signature suggestive for impaired RNA exosome function, raising the possibility that DIS3 represents a potential tumor suppressor gene in such disorders (PMID: 26305418).",,2017-01-16,,22894,DIS3,"DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease",False,ENST00000377767,NM_014953.3,KIAA1008,EXOSC11,2810028N01Rik,dis3p,RRP44,False,21343389,Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.,Cancer research,2018-04-01T20:11:00,71,7,2561-71,Rose AE et al,doi: 10.1158/0008-5472.CAN-10-2958,,0001-04-01,,26305418,A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.,Oncotarget,2018-09-22T20:15:00,6,28,26129-41,Lionetti M et al,doi: 10.18632/oncotarget.4674,,0001-09-22,,24434212,Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.,Cancer cell,2018-01-13T20:14:00,25,True,91-101,Lohr JG et al,doi: 10.1016/j.ccr.2013.12.015,,2018-01-13T01:01:00,,21430775,Initial genome sequencing and analysis of multiple myeloma.,Nature,2018-03-24T20:11:00,471,7339,467-72,Chapman MA et al,doi: 10.1038/nature09837,,0001-03-24,,22573403,Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.,Blood,2018-08-02T20:12:00,120,5,1077-86,Walker BA et al,doi: 10.1182/blood-2012-03-412981,,0001-08-02,,21289487,The eukaryotic RNA exosome: same scaffold but variable catalytic subunits.,RNA biology,2018-01-01T20:11:00,8,True,1961-06-01,Lykke-Andersen S et al,,,0001-01-01,,23319804,Genetic amplification of the NOTCH modulator LNX2 upregulates the WNT/β-catenin pathway in colorectal cancer.,Cancer research,2018-03-15T20:13:00,73,6,2003-13,Camps J et al,doi: 10.1158/0008-5472.CAN-12-3159,,0001-03-15,,24150935,Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target.,Nucleic acids research,2018-01-01T20:14:00,42,2,1270-90,Tomecki R et al,doi: 10.1093/nar/gkt930,,0001-01-01,,25521164,The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.,British journal of haematology,2018-04-01T20:15:00,169,True,57-70,Weißbach S et al,doi: 10.1111/bjh.13256,,0001-04-01,,22237025,Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.,Nature,2018-01-11T20:12:00,481,7382,506-10,Ding L et al,doi: 10.1038/nature10738,,0001-01-11,,24478024,Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression.,"Genes, chromosomes &amp; cancer",2018-04-01T20:14:00,53,4,339-48,de Groen FL et al,doi: 10.1002/gcc.22144,,0001-04-01,,25925570,The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA.,Nucleic acids research,2018-05-26T20:15:00,43,10,5182-93,Segalla S et al,doi: 10.1093/nar/gkv387,,0001-05-26,,23396385,Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules.,Blood cancer journal,2018-02-08T20:13:00,3,,e102,Leich E et al,doi: 10.1038/bcj.2012.47,,0001-02-08,
17679,GENE_SUMMARY,,"DIS3 encodes a component of the human RNA exosome complex that is involved in RNA degradation. Somatic mutations and altered expression of DIS3 occur in several cancer types, most notably multiple myeloma.",,2017-01-16,,22894,DIS3,"DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease",False,ENST00000377767,NM_014953.3,KIAA1008,EXOSC11,2810028N01Rik,dis3p,RRP44,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
